Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001737287-25-000038
Filing Date
2025-03-13
Accepted
2025-03-13 16:10:51
Documents
5
Effectiveness Date
2025-03-13
Reference 429
333-277954

Document Format Files

Seq Description Document Type Size
1 S-8 allogene-formsx8x20250313.htm S-8 84162
2 EX-FILING FEES exhibit107-formsx8x2025031.htm EX-FILING FEES 24110
3 EX-5.1 exhibit51-formsx8x20250313.htm EX-5.1 11386
4 EX-23.1 exhibit231-formsx8x20250313.htm EX-23.1 2280
5 cooleya.jpg GRAPHIC 10201
  Complete submission text file 0001737287-25-000038.txt   137166
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-285781 | Film No.: 25735859
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)